Innovent Biologics NDA for IBI311 in thyroid eye disease treatment gets priority review in China
Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company, announced that its New Drug Application (NDA) for IBI311, a pioneering treatment for Thyroid Eye Disease (TED), has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Drug Administration (NMPA). This marks a significant milestone as IBI311 is the first […]